These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35460474)

  • 1. The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan.
    Huang YH; Hsu KH; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Target Oncol; 2022 May; 17(3):295-306. PubMed ID: 35460474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs.
    Chen HY; Chen CH; Liao WC; Lin YC; Chen HJ; Hsia TC; Cheng WC; Tu CY
    BMC Pulm Med; 2024 Oct; 24(1):517. PubMed ID: 39415161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.
    Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot DM; Tan EH; Tanaka H; Wu YL; Yang JC; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N
    Lung Cancer; 2019 Jun; 132():126-131. PubMed ID: 31097085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    Liu J; Jin B; Su H; Qu X; Liu Y
    BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
    Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
    BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib for
    Xie L; Nagpal S; Wakelee HA; Li G; Soltys SG; Neal JW
    Oncologist; 2019 Jun; 24(6):836-843. PubMed ID: 30126856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.
    Ito K; Morise M; Wakuda K; Hataji O; Shimokawaji T; Takahashi K; Furuya N; Takeyama Y; Goto Y; Abe T; Kato T; Ozone S; Ikeda S; Kogure Y; Yokoyama T; Kimura M; Yoshioka H; Murotani K; Kondo M; Saka H
    ESMO Open; 2021 Jun; 6(3):100115. PubMed ID: 33984681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
    Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM
    PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.
    Hochmair MJ; Buder A; Schwab S; Burghuber OC; Prosch H; Hilbe W; Cseh A; Fritz R; Filipits M
    Target Oncol; 2019 Feb; 14(1):75-83. PubMed ID: 30539501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
    Hayashi H; Yonesaka K; Nakamura A; Fujimoto D; Azuma K; Sakata S; Tachihara M; Ikeda S; Yokoyama T; Hataji O; Yano Y; Hirano K; Daga H; Okada H; Chiba Y; Sakai K; Nishio K; Yamamoto N; Nakagawa K
    Lung Cancer; 2022 Jun; 168():38-45. PubMed ID: 35477147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer.
    Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
    Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O
    Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis.
    Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C
    Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N; Mera T; Märten A; Hochmair MJ
    Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.